Payment overview · 2025
General Payments
$3,621.97
80 reported records · 25 companies
Healthcare provider profile · identity verified
Biju T Mathews, MD
Allopathic & Osteopathic Physicians|General Practice · TITUSVILLE, FL · NPI 1386692804
Verified facts
What the public records show
CMS Open Payments records show Biju T Mathews, MD received $3,621.97 in general payments during 2025 across 80 reported records.
Shockwave Medical, Inc accounted for 20.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 691 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 691 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $746.21 | 20.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $696.27 | 19.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $463.27 | 12.8% | 11 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $303.30 | 8.4% | 9 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$241.54 | 6.7% | 3 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $200.80 | 5.5% | 12 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $110.94 | 3.1% | 5 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $105.63 | 2.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $96.62 | 2.7% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $87.38 | 2.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $77.36 | 2.1% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $74.09 | 2.0% | 5 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $72.99 | 2.0% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $64.02 | 1.8% | 3 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $47.68 | 1.3% | 2 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $38.59 | 1.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $37.19 | 1.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.16 | 0.8% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $24.46 | 0.7% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $21.14 | 0.6% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.79 | 0.6% | 1 | 2025 |
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $17.77 | 0.5% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $15.79 | 0.4% | 1 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $15.36 | 0.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.62 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,946.97 | 79 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $675.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $746.21 | 5 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $218.94 | 2 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $153.58 | 8 | 2025 |
Source payment records
|
|||||
| ACCOLADE SR Normalized: accolade sr |
Device | Boston Scientific Corporation | $147.02 | 1 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $110.94 | 5 | 2025 |
Source payment records
|
|||||
| General - Balloon Catheters Normalized: general balloon catheters |
Device | Boston Scientific Corporation | $110.92 | 1 | 2025 |
Source payment records
|
|||||
| TURNPIKE Normalized: turnpike |
Device | Teleflex LLC | $105.63 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $96.62 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $87.38 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $77.36 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $64.02 | 3 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $56.88 | 4 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $47.68 | 2 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $47.22 | 4 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL Normalized: mynx control |
Device | CORDIS US CORP. | $44.15 | 1 | 2025 |
Source payment records
|
|||||
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $43.59 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $38.59 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $31.58 | 1 | 2025 |
Source payment records
|
|||||
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $29.34 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $29.16 | 1 | 2025 |
Source payment records
|
|||||
| RAIN SHEATH Normalized: rain sheath |
Device | CORDIS US CORP. | $28.84 | 1 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| General - EP Normalized: general ep |
Device | Boston Scientific Corporation | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| General - CRM_CRM Normalized: general crm crm |
Device | Boston Scientific Corporation | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| ZILVER PTX Normalized: zilver ptx |
Device | Cook Medical LLC | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $12.90 | 1 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $12.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 691 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 31 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 97 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | 16 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
691 | 180 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
97 | 17 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
135 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
691 | 180 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 1505 | 506 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1153 | 382 |
| Clopidogrel | Clopidogrel Bisulfate | 1073 | 326 |
| Amlodipine Besylate | Amlodipine Besylate | 980 | 297 |
| Atorvastatin Calcium | Atorvastatin Calcium | 814 | 265 |
| Losartan Potassium | Losartan Potassium | 725 | 252 |
| Eliquis | Apixaban | 691 | 180 |
| Xarelto | Rivaroxaban | 613 | 157 |
| Carvedilol | Carvedilol | 600 | 172 |
| Lisinopril | Lisinopril | 410 | 134 |
| Potassium Chloride | Potassium Chloride | 407 | 155 |
| Ezetimibe | Ezetimibe | 389 | 112 |
| Furosemide | Furosemide | 382 | 166 |
| Nitroglycerin | Nitroglycerin | 362 | 234 |
| Metoprolol Tartrate | Metoprolol Tartrate | 307 | 106 |
| Valsartan | Valsartan | 245 | 94 |
| Hydrochlorothiazide | Hydrochlorothiazide | 241 | 72 |
| Atenolol | Atenolol | 227 | 67 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 223 | 86 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 209 | 60 |
| Spironolactone | Spironolactone | 193 | 70 |
| Amiodarone Hcl | Amiodarone Hcl | 187 | 70 |
| Nebivolol Hcl | Nebivolol Hcl | 164 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 149 | 49 |
| Entresto | Sacubitril/Valsartan | 135 | 46 |
| Warfarin Sodium | Warfarin Sodium | 133 | 30 |
| Repatha Sureclick | Evolocumab | 131 | 26 |
| Digoxin | Digoxin | 115 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 115 | 38 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 114 | 41 |
| Mounjaro | Tirzepatide | 97 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 92 | 31 |
| Sotalol | Sotalol Hcl | 84 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 29 |
| Jantoven | Warfarin Sodium | 72 | 15 |
| Simvastatin | Simvastatin | 55 | 19 |
| Ranolazine Er | Ranolazine | 54 | 18 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 50 | 18 |
| Ozempic | Semaglutide | 50 | 13 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 49 | 25 |
| Telmisartan | Telmisartan | 49 | 16 |
| Brilinta | Ticagrelor | 41 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 39 | 18 |
| Prasugrel Hcl | Prasugrel Hcl | 34 | 11 |
| Nifedipine Er | Nifedipine | 33 | 12 |
| Vascepa | Icosapent Ethyl | 33 | 12 |
| Irbesartan | Irbesartan | 32 | suppressed |
| Bumetanide | Bumetanide | 31 | 16 |
| Jardiance | Empagliflozin | 31 | 16 |
| Diltiazem 24hr Er | Diltiazem Hcl | 30 | 12 |
| Torsemide | Torsemide | 30 | 11 |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Praluent Pen | Alirocumab | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 26 | suppressed |
| Repatha Syringe | Evolocumab | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 24 | suppressed |
| Klor-Con 10 | Potassium Chloride | 24 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Multaq | Dronedarone Hcl | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 16 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Dofetilide | Dofetilide | 13 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,621.97 · 80 records | Shockwave Medical, Inc | ACCOLADE SR, AMVUTTRA, AURYON LASER SYSTEM 100-120 VAC, AVVIGO Guidance System, Assure WCD, Barostim Neo System, CAMZYOS, CAPVAXIVE, CARDIVA VASCADE MVP VVCS 6-12F, CARDIVA VASCADE MVP XL VVCS 10-12F, CARTO 3, COREVALVE EVOLUT R, ELIQUIS, ELUVIA, EMBLEM MRI S-ICD, ESPRIT, FARAPULSE, General - Balloon Catheters, General - CRM_CRM, General - EP, IN.PACT ADMIRAL, Indigo System, JARDIANCE, LEQVIO, LUX-Dx Insertable Cardiac Monitor, LifeVest, MOUNJARO, MYNX CONTROL, Optimizer, RAIN SHEATH, ROTAPRO, Repatha, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TURNPIKE, UPTRAVI, VERQUVO, VYNDAQEL, WATCHMAN FLX, ZEPBOUND, ZILVER PTX | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error